Abbott Laboratories (ABT) Monday released encouraging results from five abstracts evaluating levodopa-carbidopa intestinal gel, or LGIC, its investigational compound for advanced Parkinson's disease.
The global health care company stated that these abstracts include the results from the second interim analysis of a long-term safety and tolerability trial, as well as secondary endpoint analyses from the Phase 3 pivotal trial.
The company stated that LCIG is an investigational therapy that is currently being evaluated in patients with advanced Parkinson's disease in additional Phase 3 clinical trials. The company further added that levodopa-carbidopa is administered in gel form, directly into the small intestine via a procedurally-implanted tube connected to a portable pump that delivers continuous supply of LCIG during awake hours.
Abbott stated that in a 54 week open-label safety and tolerability study of 354 patients with advanced Parkinson's disease, the primary endpoint of safety showed adverse events were mostly mild to moderate, were generally associated with the Percutaneous Endoscopic Gastrostomy tube placement procedure and its complications, were transient, and resolved over time.
For comments and feedback: editorial@rttnews.com